Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2005-02-15
2005-02-15
Nguyen, Dave T. (Department: 1635)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S069100, C514S04400A
Reexamination Certificate
active
06855549
ABSTRACT:
The present invention involves methods and compositions for increasing the susceptibility of target cells to transduction by gene transfer vectors. Specifically, it is proposed that increasing intracellular permeability in epithelial tissue increases the percentage of input vector that will transduce that target tissue. Specific examples show that receptors for retrovirus are preferentially accessible on the basolateral surface of airway epithelia, and permeabilizing such tissues results in greater infection with retrovirus. This has important implications in gene therapy, for example, to treat cystic fibrosis with the CFTR gene.
REFERENCES:
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5196335 (1993-03-01), Groner
patent: 5252479 (1993-10-01), Srivastava
patent: 5354855 (1994-10-01), Cech et al.
patent: 5359046 (1994-10-01), Capon et al.
patent: 5543399 (1996-08-01), Riordan et al.
patent: 5641662 (1997-06-01), Debs et al.
patent: 5658894 (1997-08-01), Weisz
patent: 5756353 (1998-05-01), Debs
patent: 5962429 (1999-10-01), Welch
patent: WO 9007469 (1990-07-01), None
patent: WO 9312240 (1993-06-01), None
patent: WO 9622765 (1996-08-01), None
patent: WO 9627393 (1996-09-01), None
patent: WO 9632116 (1996-10-01), None
Lacaz-Vieira (Journal of General Physiology, (Dec. 1997) 110 (6) 727-40).*
Sakoff et al (Biochemical and Molecular Medicine, (Apr. 1997) 57 (2) 81-90).*
Cho et al (Pharmaceutical Research, (Apr. 1990) 7 (4) 325-31).*
Noach et al (International Journal of Pharmaceutics (1993), 90(3), 229-37).*
Allen et al (Development, (Apr. 1990) 108 (4) 623-34).*
Mariadason et al (Am. J. Physiol. (1997) 272:G705-G712.*
Marano et al (Biochem. Biophys. Res. Comm. (1995) 209(2):669-676).*
Wong et al (J. Cell Biol. (1997) 1363(2): 399-409).*
Li et al (Biochimica Et Biophysica Acta, (Dec. 14, 1990) 1030 (2) 297-300).*
The Dictionary of Cell and Molecular Biology (retrieved from http://www.mblab.gla.ac.uk/˜julian/Dict.html on May 9, 2003.*
Jiang et al (Eur. J. Hum. Genet. (1998) 6(1):12-31).*
Rodgers et al (Eur. Respir. J (2001): 17:1314-1321).*
O'Dea et al (Current Gene Therapy (2002) 2:173-181).*
Ferrari et al (Clin Exp. Immunol. (2003) 132: 1-8).*
Kaplan et al (Human Gene Therapy (1998) 9(10):1469-1479).*
Kleeberger et al (Applied Phys. (1992) 72(2): 670-676).*
Johnson et al (J. Virol. (1998) 72(11):8861-8872).*
Olsen et al (Nucl. Acids Res. (1993) 21(3):663-669).*
Quinn et al (J. Cell. Phys (1996) 168(1):34-41.*
Katkin et al (Human Gene Therapy 1997 3(9):75-779).*
Cornetta et al (J. Virol. Methods (1989) 23(2): 187-194).*
Debs et al (J. Immunol. 1988 140(10): 3482-3488).*
Jongeneel et al (Nucl. Acids Res. (1980) 8(7): 1661-1673).*
Tomita et al (Journal of Pharmaceutical Sciences, (1996 Jun) 85 (6) 608-11).*
Zegarra-Moran et al (British Journal of Pharmacology, (1995 Mar) 114 (5) 1052-6).*
Meza et al (Journal of Cellular Biochemistry, (1982) 18 (4) 407-21).*
McEwan et al (Biochim. Biophys. Acta (1993) 1148(1):51-60.*
Arcasoy et al (Gene Therapy (1997) 4(1): 32-38).*
Richardson et al (Lab. Invest. (1976) 35(4): 307-314).*
Yap et al (Exp. Cell Res. (1995) 218(2): 540-550).*
Hahimoto et al (Biochim. Biophys. Acta (1997) 1323(2): 281-290).*
Welsh et al (J. Clin. Invest. (1985) 76: 155-1168).*
Flasshove et al (Blood (1995) 85(2): 566-574).*
Wunderlich et al (Archives of Virology, (1982) 73 (2) 171-83).*
Orkin et.al.; Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995.*
Verma et.al.; Gene therapy- promises, problems and prospects, 1997, Nature, vol. 389: 239-242.*
Rosenecker et.al.; Toward Gene Therapy of Cystic Fibrosis, 1998, Eur. J Med. Res. 3: 149-156.*
Davies et.al.; Prospects for gene therapy for cystic fibrosis, 1998, Molecula Medicine Today: 292-299.*
Wilson; Gene Therapy for Cystic Fibrosis: Challenges and Future Directions, 1995, J Clin. Invest., vol. 96: 2547-2554.*
Flotte et.al.; Gene Therapy in Cystic Fibrosis, 2001, Chest 120: 124S-131S.*
Rosenfeld et.al.; Gene Therapy for Cystic Fibrosis, 1996, Chest 109: 241-252.*
Yamaguchi et.al.; Differential Effects of Transforming Growth Factor-B on Osteoclast-Like Cell Formation in Mouse Marrow Culture: Relation to the Effect of Zinc-Cheklating Dipeptides, 1995, Peptides, vol. 16, No. 8: 1483-1488.*
Mallea et.al.; Modulation of stimulatory action of follicle stimulating hormone (FSH) and inhibitory action of epidermal growth factor (EGF) on aromatase activity in Sertoil cells by calcium, 1987, FEB, vol. 218, No. 1: 143-147.*
Halbert et.al.; Retroviral Vectors Efficiently Transduce Basal and Secretory Airway Epithelial Cells In Vitro Resulting om Persistent Gene Expression in Organotypic Culture, 1996, Human Gene Therapy 7: 1871-1881.*
Boucher; Status of gene therpay for cystic fibrosis lung disease, 1999, Journal of Clinical Investigation, vol. 103, No. 4: 441-445.*
Boucher; Current status of CF gene therapy, 1996, TIG, vol. 12., No. 3: 81-84.*
Alton; Gene therapy: the case for cystic fibrosis, 1997, Journal of the Royal Society of Medicine: 43-46.*
Medline: 2001324122.*
Medline 83073940.*
Alexander et al., “DNA-damaging agents greatly increase the transition of nondividing cells by adeno-associated virus vectors,”J. Virol.,68, 8282-8287, 1994.
Alexander et al. “Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results,”Hum. Gene Ther.,8:1911-1902, 1997.
Anderson et al., “Demonstration that CFTR is a chloride channel by alteration of its anion sleectivity,”Science,253:202-205, 1991.
Anderson and Van Itallie, “Tight junctions and the molecular basis for regulation of paracellular permeability,”Am. J. Physiol.,269:G467-G475, 1995.
Basak and Compans, “Polarized entry of canine parovirus in an epithelial cell line,”J. Virol.,63:3164-3167, 1989.
Bhat et al., “Regulation of tight junction permeability by calcium mediators and cell cytoskeleton in rabbit tracheal epithelium,”Pharm. Res.,10:991-997, 1993.
Blau and Compans, “Entry and release of measles virus are polarized in epithelial cells,”Virology,210:91-99, 1995.
Bosch et al., “Proliferation induced by keratinocyte growth factor enhances in vivo retroviral-mediated gene transfer to mouse hepatocytes,”J. Clin. Invest.,98:2683-2687, 1996.
Bosch et al., “Effects of keratonocyte and hepatocyte growth factor in vivo: Implication for retrovirus-mediated gene transfer to liver,”Hum. Gene Ther.,9:1747-1754, 1998.
Boucher et al., “Airway transepithelial electric potential in vivo: species and regional differences,”J. Appl. Physiol.,48:169-176, 1980.
Bowles et al., “A simple and efficient method for the concentration and purification of recombinant retrovirus for increased hepatocyte transduction in vivo,”Hum. Gene Ther.,7:1735-1742, 1996.
Cereijido et al., “Role of tight junctions in establishing and maintaining cell polarity,”Annu. Rev. Physio.,60:161-177, 1998.
Chan et al., “Regional deposition of nebulized hypodense nonisotonic solutions in the human respiratory tract,”Eur. Respir. J.,7:1483-1489, 1994.
Chu et al., “Binding and uptake of cationic lipid:pDNA complexes by polarized airway epithelial cells,”Hum. Gene Ther.,10:25-36, 1999.
Clayson and Compans, “Entry of simian virus 40 is restricted to apical surfaces of polarized epithelial cells,”Mol. Cell Biol.,8:3391-3396, 1988.
Colledge et al., “Generation and characterization of a ΔF508 cystic fibrosis mouse model,”Nature Genet.,10:445-452, 1995.
Denker and Nigam, “Molecular structure and assembly of the tight junction,”Am J Physiol,274:F1-F9, 1998.
Drumm et al., “Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer,”Cell,62:1227-1233, 1990.
Duan et al., “Structural and functional heterogeneity of interated recombinant AAV genomes”Virus Res.,48:41-56, 1997.
Duan et al., “Circular intermediates of recombinant a
Bodner Mordechai
Davidson Beverly
Herrmann Steven M.
Jolly Douglas J.
McCray, Jr. Paul B.
Chiron Corporation
Fulbright & Jaworski LLP
Nguyen Dave T.
Schnizer Richard
The University of Iowa Research Foundation
LandOfFree
Methods and compositions for increasing the infectivity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for increasing the infectivity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for increasing the infectivity of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3497046